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- 14.2] for arm A, 9.2 m [7.4 - 10.5] for arm B. TTP was 5.4 m in arm 
A and 5.7 in arm B. There were 1 grade III/IV haematological toxicities 
in arm A (1.2%) and 2 in arm B (2.4%). There were 4 grade III/IV non 
haematological toxicities in arm A (4.8%) and 6 in arm B (7.3%). 
Conclusion: The switch between the two regimen is feasible without 
any major toxicities. Despite higher response rate in favour of the 
switch strategy, OS and TTP are similar between the two arms. A new 
censor date is ﬁxed at 1st June 2007. Overall survival and TTP will be 
updated for a ﬁnal analysis.
SD n = 87 PD (%) SD (%) OR (%) NA (%)
Arm A (n = 45) 24.4 53.3 15.6 6.6
Arm B (n = 42) 11.9 59.5 21.4 7.1
95% CI ORR ; Arm A: 15.6 [6.49 - 29.45] ;  Arm B: 21.4 [10.3 - 36.81]
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in patients with advanced non-small cell lung cancer (NSCLC)
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Background: Imatinib inhibits activated PDGF-Rβ and down-regu-
lates VEGF resulting in decreased angiogenesis and improved blood 
ﬂow favoring enhanced tumor drug delivery. 
Objectives: 1) determine the MTD for the combination of imatinib and 
cisplatin plus docetaxel in NSCLC pts, 2) describe non-dose limiting 
toxicities (non-DLT), 3) evaluate for feasibility and changes tumor 
angiogenesis measurement by DCE-MRI after treatment with imatinib. 
DCE-MRI detects speciﬁc properties of vascular beds by virtue of the 
differential distribution of contrast media in normal and pathological 
regions. 
Methods: Eligibility: NSCLC with tumor expression of p-PDGF-Rβ. 
DCE-MRI was performed before and after 7 daily doses of imatinib 
alone (lead-in) followed by cisplatin plus docetexel on day 1, every 
3 weeks. Once daily imatinib was given with each cisplatin plus 
docetaxel cycle, on days -5 to +2. Standardized hemodynamic param-
eters (Ktrans, Ve, Kep) were acquired from DCE-MRI. 
Results: 14 enrolled pts (9 M, 5 F) were evaluable for toxicity and 13 
for response. Six pts were treated at dose level 1 (C+D 60/60 mg/m2, 
and I 300 mg); one DLT (febrile neutropenia) was seen; there were 
no DLTs in cohort 2 (60/60 mg/m2 and I 400mg; n=3), and two DLTs 
were observed in cohort 3 (70/70 mg/m≥ and I 400mg; n=5) - febrile 
neutropenia and grade 4 diarrhea. For all cohorts, grade 3 and 4 toxici-
ties were: fatigue (7%), nausea (14%), neutropenia (14%), elevated 
creatinine (7%), and dispnea (7%). Two pts (15%) had partial response, 
and 6/13 pts had stable disease as their best response. DCE-MRI dem-
onstrated trend in decrease of Ve after 7-day treatment with imatinib 
(p=0.088). 
Conclusion: MTD for imatinib and cisplatin plus docetaxel in chemo 
naïve NSCLC pts is 400 mg and 60/60 mg/m≥, respectively. More, 
DCE-MRI is feasible in NSCLC pts. DCE-MRI measured reduction 
in tumor extracellular extravascular space (Ve) suggests decrease in 
intra-tumoral pressure after PDGF-Rβ inhibition, which could mean 
improvement in tumor drug delivery. Further studies exploring DCE-
MRI as an imaging biomarker-predictor to antiangiogenic therapy in 
patients with NSCLC are ongoing.
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Background: Brain metastases are a common feature of non-small-
cell lung cancer (NSCLC) and are gaining more and more attention, 
as combined modality treatment and efﬁcient new drug therapies have 
improved local control and overall survival rates. The clinical man-
agement of brain metastases is of critical importance to prevent rapid 
disease deterioration and symptom-driven worsening of quality of 
life. Therapeutic options for cranial progression after previous whole 
brain irradiation and chemotherapy-induced tumor remission are very 
limited. No established therapeutic approaches exist for cranial relapse 
after response to previous radiotherapy and systemic chemotherapy. 
Casuistry reporting of experiences with new agents in such patients 
may help to build up a rationale for new therapy sequences in this hard-
to-treat patient population.
Methods: Presented are two case reports arising from our hospitals’ 
two-years lasting clinical experience with erlotinib, a TK-EGFR-in-
hibitor approved to treat patients with locally advanced or metastatic 
NSCLC after failure of at least one prior chemotherapy regimen. Erlo-
tinib was used in accordance with prescribing information as third-line 
therapy in two non-smoking women, one with adenocarcinoma and the 
other one with bronchioloalveolar carcinoma histology. Both patients 
were initially staged M+ due to distant lymph node and contra-lateral 
pulmonary tumor manifestation.
Results: After occurrence of brain metastases in autumn 2004, both 
patients underwent standard whole brain irradiation with 40 Gy. The 
well-tolerated radiotherapy was followed by second-line chemotherapy 
which resulted in both cases into a consolidation of the thoracic and 
cranial tumor manifestation for around six months. Pulmonary and 
cerebral progression requested in both cases for a therapeutic alter-
native. Tyrosine kinase (TK) inhibition began in July respectively 
October 2005. In the ﬁrst patient, therapy was stopped despite ongoing 
cranial and pulmonary remission after 9 months due to the appear-
ance of hepatic metastasis. In the second patient, erlotinib therapy was 
continued for 15 months with a lasting cranial (CR) and thoracic (PR) 
remission. Surgery (partial laminectomy of axis and atlas) plus post-op-
erative cranial-cervical irradiation (40 Gy) were adequate measures to 
control beginning osseous metastasis in September 2006. After signs of 
pulmonary recurrence, therapy was stopped in December 2006. In both 
patients, the therapy was well tolerated with minimal side effects and 
improved quality of life scores. With view to the generally poor prog-
nosis of metastatic brain cancer with its median survival of 3-4 months, 
the sustained objective remission and control of cranial metastases for 
about 9 respectively more than 15 months is noteworthy.
Conclusions: The ability of TK-inhibitors as erlotinib to induce objec-
tive remissions in brain metastases which occurred after initial whole 
brain irradiation and which relapsed after previous chemotherapy, 
requires attention. The observed total survival times of above 18 
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respectively 24 months since occurrence of cranial disease manifesta-
tion in line with a considerable quality of life improvement asks to 
investigate more systematically the best use of targeted therapies after 
whole brain irradiation.
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Different EGFR mutation patterns are associated with survival and 
response to first-line chemotherapy in NSCLC
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Purpose: EGFR mutations deﬁne a subset of NSCLC with sensitivity 
to geﬁtinib or erlotinib. However, all EGFR mutations are not equal 
and may have different predictive and prognostic value. In this study 
we compared classical “hot spot” and “rare” EGFR mutations in terms 
of response to 1st line chemotherapy and overall survival in a cohort of 
patients with advanced NSCLC.
Patients and Methods: Tumor samples were formalin ﬁxed parafﬁn-
embedded tissues that were microdissected to achieve purity 80% in 
cancer cells. EGFR mutations were analyzed by DNA sequencing of 
exons 18 to 21 in both forward and reverse directions in PCR products 
from tumor genomic DNA. 
Results: Of the 169 patients assessable for mutation detection we 
found 12 (7%) positive for classical “hot spot” (G719D, Del 19, 
E746V, L747S, L858R) EGFR mutations and 34 (20%) positive for 
“rare” EGFR mutations. Classical but not rare mutations were associ-
ated with female gender and never smoking history (P=0.002; P<0.001 
and P=0.637; P=0.402, respectively). However, the histological type 
had no signiﬁcant association with either type of EGFR mutations 
(P=0.520 and P=0.260, respectively).
Response rates to ﬁrst-line chemotherapy were signiﬁcantly higher 
in patients bearing classical mutations (60%) but not in those with 
rare EGFR mutations (29%) as compared with patients with wild-
type EGFR (20.4%) (p=0.005 and p=0.311, respectively). Time to 
tumor progression was 65 weeks, 22 weeks and 33 weeks for patients 
with classical mutations, rare EGFR mutations and wild type EGFR, 
respectively (p=0.165 and p=0.327 as compared to wild type). Overall 
survival was longer in patients bearing classical mutations (p=0.006) 
but not in those with rare mutations (p=0.843) as compared to patients 
with wild type EGFR.
Conclusions: Different EGFR mutation patterns are associated with 
higher response to ﬁrst-line chemotherapy and longer overall survival 
in patients with advanced NSCLC. 
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Background: EGFR mutations in non-small-cell lung cancer (NSCLC) 
are associated with sensitivity to geﬁtinib and erlotinib. However, the 
correlation of EGFR mutation status between primary tumor and me-
tastases is not established. To investigate this, we analyzed 18 patients 
with paired samples of primary and metastatic NSCLC.
Methods: Tumor metastases include adrenal gland, liver, bone, brain, 
lung, skin and thoracic wall. All tumor samples were formalin ﬁxed 
parafﬁn-embedded tissues. Exons 18, 19, 20 and 21 of the EGFR were 
ampliﬁed by PCR and the products were directly sequenced on an ABI 
3100 Avant genetic analyzer. All mutations were conﬁrmed by sequenc-
ing in both directions and by an independent PCR ampliﬁcation.
Results: In 12 cases there was concordance between the primary tumor 
and the corresponding metastases, with EGFR status determined as 
wild type. Discordance was observed in six cases (33.3%): in three 
cases EGFR was mutated only in the primary tumor, while in two cases 
EGFR mutations were found only in metastases. Finally, in one patient 
the metastases had an additional mutation besides that of the primary 
tumor. Two out of 18 patients carried the L692P-V717A and T847A 
mutations respectively only in their metastases. The time to tumor 
progression (TTP) in 1st line chemotherapy was 29 weeks for the 
patient carrying the double mutation (L692P-V717A) and 307 weeks 
for the patient carrying the T847A mutation. Seven out of 18 patients 
were treated with geﬁtinib. Three of them had no mutations in both 
the primary and metastatic tumors and the median TTP was 20 weeks. 
Three patients carried the E746V, L692P and G857E mutations, respec-
tively, in their primary tumors but were wild type in their metastases. 
Interestingly, these patients received RTK inhibitors prior to develop-
ing the metastases. The median TTP for them was 59 weeks. The last 
patient who carried the Del 19 in his primary tumor and the Del 19 and 
T790M in his metastases received geﬁtinib before the second surgery 
and exhibited TTP of 80 weeks.
Conclusions: Our ﬁndings suggest a discordance of EGFR mutation 
status between primary tumor and metastases and imply a possible role 
for EGFR mutation analysis of metastases for the treatment of meta-
static NSCLC with RTKIs.
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Background: Geﬁtinib is an effective treatment for chemotherapy-
resistant East Asian NSCLC patients. The efﬁcacy of geﬁtinib in che-
monaive NSCLC patients bearing different types of EGFR mutations in 
their tumor tissue and who are candidates for standard chemotherapy is 
unclear. It is important to know the precise response rates and response 
durations of geﬁtinib in these patients in order to compare this novel 
approach with standard chemotherapy. 
